Skinvisible, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 12:59 pm EST
Share
Skinvisible, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.009316 million compared to USD 0.111421 million a year ago. Net loss was USD 0.418068 million compared to USD 0.203352 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.09 compared to USD 0.04 a year ago.
For the nine months, sales was USD 0.274296 million compared to USD 0.410571 million a year ago. Net loss was USD 0.82431 million compared to USD 0.907371 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to USD 0.2 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare and formulated over forty topical skin products. The Company's product, Pivotal, is a patented polymer delivery system technology Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents.
SKINVISIBLE, INC. 
